Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize
COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines

  * Agreement provides patients with broader access to a protein-based non-mRNA
    adjuvanted COVID-19 vaccine through combined commercial strength, from 2025
    onwards
  * Accelerates potential for development of a novel flu-COVID-19 combination
    product based on authorized vaccines with demonstrated efficacy and
    tolerability, potentially offering patients enhanced convenience and
    protection

Paris and Gaithersburg, Md., United States. May 10, 2024. As part of Sanofi's
commitment to developing a diverse portfolio of best-in-class vaccines, the
company has entered into a co-exclusive licensing agreement with Novavax, a
biotechnology company headquartered in Maryland, US.
The terms of the agreement include: a co-exclusive license to co-commercialize
Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide (except in
countries with existing Advance Purchase Agreements and in India, Japan, and
South Korea where Novavax has existing partnership agreements); a sole license
to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's
flu vaccines; and a non-exclusive license to use the Matrix-M adjuvant in
vaccine products. In addition, Sanofi will take a minority (Â